REPRIEVE - Randomized Trial to Prevent Vascular Events in HIV

A prospective, double-blind, randomized, placebo-controlled, multicenter phase IV efficacy study that will examine the effects of 4 mg daily pitavastatin on cardiovascular-related events among HIV-1 infected adults who are currently on ART.

This research study is led by Dr. Daniel Skiest.

Contact: Frances Santiago, RN, 413-794-7365

Participation details:

HIV, Heart
Baystate Infectious Diseases Clinical Research, 3300 Main Street, Springfield, MA 01199
HIV-1 infected men and women ≥40 and ≤75 years of age, on any ART regimen (ART not provided by the study) for at least 6 months prior to study entry, with any plasma HIV-1 RNA level, with CD4+ T-cell count >100 cells/mm3 not meeting 2013 ACC/AHA guideline thresholds for recommended statin initiation.